lbpharma.us
About company
LB is focused on the multi-billion dollar US antipsychotic market and is developing a proprietary, patented version of amisulpride. Amisulpride is a successful anti-psychotic drug approved in Europe with millions of prescriptions filled throughout Europe/CIS/PacRim yearly comprising a market share within schizophrenia of 5-10% (depending on the country). Well-controlled trials stretching back twenty years have documented amisulpride’s effective treatment of the negative symptoms of schizophrenia as well as depressive disorders. More specifically, the data shows that amisulpride is one of the most effective antipsychotics in the world with no statistically significant difference in efficacy between amisulpride and the two drugs that currently comprise 40% of the US market.
